Management of Helicobacter pylori infection

References

• Warren JR, Marshall BJ. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulcer ulceration. Lancet1, 1273–1275 (1983).
   PubMed Web of Science ®Google Scholar
• Wotherspoon AC, Doglioni C, Diss TC et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet342, 575–577 (1993).
   PubMed Web of Science ®Google Scholar
• D’Elios MM, Appelmelk BJ, Amedei A et al. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol. Med.7, 316–323 (2004).
   Web of Science ®Google Scholar
• No authors listed. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum.61, 1–241 (1994).
   PubMedGoogle Scholar
• Ogura K, Hirata Y, Yanai A et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J. Clin. Gastroenterol.42, 279–283 (2008).
   PubMed Web of Science ®Google Scholar
• Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J. Clin. Invest.119, 2475–2487 (2009).
   PubMed Web of Science ®Google Scholar
• Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin. Microbiol. Rev.20, 280–322 (2007).
   PubMed Web of Science ®Google Scholar
• Bayerdorffer E, Oertel H, Lehn N et al. Topographic association between active gastritis and Campylobacter pylori colonisation. J. Clin. Pathol.42, 834–839 (1989).
   PubMed Web of Science ®Google Scholar
• Trebesius K, Panthel K, Strobel S et al. Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation. Gut46, 608–614 (2000).
   PubMed Web of Science ®Google Scholar
• Zullo AA, Hassan C, Lorenzetti R, Winn S, Morini S. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig. Dis. Liver Dis.35, 357–361 (2003).
   PubMedGoogle Scholar
• Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut56, 772–781 (2007).
   PubMed Web of Science ®Google Scholar
• Oleastro M, Menard A, Santos A et al. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J. Clin. Microbiol.41, 397–402 (2003).
   PubMed Web of Science ®Google Scholar
• Glocker E, Kist M. Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach. J. Clin. Microbiol.42, 2241–2246 (2004).
   PubMedGoogle Scholar
• Ribeiro ML, Gerrits MM, Benvengo YH et al. Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP. FEMS Immunol. Med. Microbiol.40, 57–61 (2004).
   PubMedGoogle Scholar
• D’Elios MM, Amedei A, Benagiano M, Azzurri A, Del Prete G. Usefulness of 13C-urea breath test in the diagnosis of gastric Helicobacter pylori infection. Int. J. Immunopathol. Pharmacol.13, 27–30 (2000).
   PubMedGoogle Scholar
• Gisbert JP, Pajares JM. Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection – a critical review. Aliment. Pharmacol. Ther.20, 1001–1017 (2004).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter9, 347–368 (2004).
   PubMedGoogle Scholar
• Hoang TT, Wheeldon TU, Bengtsson C, Phung DC, Sorberg M, Granstrom M. Enzyme-linked immunosorbent assay for Helicobacter pylori needs adjustment for the population investigated. J. Clin Microbiol.2, 627–630 (2004).
   Google Scholar
• Obata Y, Kikuchi S, Miwa H, Yagyu K, Lin Y, Ogihara A. Diagnostic accuracy of serological kits for Helicobacter pylori infection with the same assay system but different antigens in a Japanese patient population. J. Med. Microbiol.52, 889–892 (2003).
   PubMedGoogle Scholar
• Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet359, 14–22 (2002).
   PubMed Web of Science ®Google Scholar
• Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med.344, 967–973 (2001).
   PubMed Web of Science ®Google Scholar
• Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet359, 9–13 (2002).
   PubMed Web of Science ®Google Scholar
• Vergara M, Catalan M, Gisbert JP et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment. Pharmacol. Ther.21, 1411–1418 (2005).
   PubMed Web of Science ®Google Scholar
• DuBois S, Kearney DJ. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am. J. Gastroenterol.100(2), 453–459 (2005).
   PubMed Web of Science ®Google Scholar
• Annibale B, Marignani M, Monarca B et al. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann. Intern. Med.131, 668–672 (1999).
   PubMed Web of Science ®Google Scholar
• Gasbarrini A, Franceschi F, Tartaglione R et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet352, 878 (1998).
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Kanamori H, Yamato H et al. Randomized study of H. pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. Ann. Hematol.84, 807–811 (2005).
   PubMedGoogle Scholar
• Fuccio L, Laterza L, Zagari RM, Cennamo V, Grilli D, Bazzoli F. Treatment of Helicobacter pylori infection. Br. Med. J.337, a1454 (2008).
   PubMedGoogle Scholar
• Megraud F. Helicobacter pylori and antibiotic resistance. Gut56, 1502 (2007).
   PubMed Web of Science ®Google Scholar
• Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin. Gastroenterol. Hepatol.7, 145–148 (2009).
   PubMed Web of Science ®Google Scholar
• Francois F, Blaser MJ. Improving Helicobacter pylori eradication regimens. Ann. Intern. Med.44, 140–141 (2006).
   Google Scholar
• Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut56, 1353–1357 (2007).
   PubMed Web of Science ®Google Scholar
• Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am. J. Gastroenterol.101, 488–496 (2006).
   PubMed Web of Science ®Google Scholar
• Lamouliatte H, Megraud F, Delchier JC et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment. Pharmacol. Ther.18, 791–797 (2003).
   PubMed Web of Science ®Google Scholar
• Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am. J. Gastroenterol.98, 562–567 (2003).
   PubMed Web of Science ®Google Scholar
• O’Morain C, Borody T, Farley A et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment. Pharmacol. Ther.17, 415–420 (2003).
   PubMedGoogle Scholar
• Abbas Z, Yakoob J, Abid S et al. Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy. Dig. Dis. Sci.54, 1953–1957 (2009).
   PubMedGoogle Scholar
• Cheng H, Hu FL. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J. Gastroenterol.15, 860–864 (2009).
   PubMed Web of Science ®Google Scholar
• Borody TJ, Pang G, Wettstein AR et al. Efficacy and safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection. Aliment. Pharmacol. Ther.23, 481–488 (2006).
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Schultze V, Rosenkranz B et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a Phase I study. Gastroenterology135, 787–795 (2008).
   PubMed Web of Science ®Google Scholar
• Rupnow MF, Chang AH, Shacter RD, Owens DK, Parsonnet J. Cost–effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J. Infect. Dis.200, 1311–1317 (2009).
   PubMed Web of Science ®Google Scholar